Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Adaptive Trials Could Have A Steep Regulatory Learning Curve

Executive Summary

Sponsors should take care that drug development efficiencies gained with the advent of adaptive clinical trials aren't offset by lack of opportunity to reflect on data from one trial to the next and "design a thoughtful, complete program," FDA warns in its draft guidance for adaptive trial design

You may also be interested in...



Adaptive Clinical Trial Designs: US FDA Provides Checklist To Begin Study

Draft guidance specifies documentation that must be submitted to FDA prior to conducting an adaptive trial, and what to include in an application.

FDA Sets New Goal For Biosimilar, Drug Promotion Guidances

Agency plans to issue 102 new and revised draft guidances this year, including those on use of multiple endpoints in clinical trials, 180-day exclusivity, and ANDA refuse-to-receive standards.

Adaptive Trials Guidance For Pediatric Drugs Will Draw On Device Advice

FDA’s centers may slingshot development work on how best to use control data.

Related Content

Topics

UsernamePublicRestriction

Register

PS051989

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel